Analyst Sam Slutsky of LifeSci Capital maintained a Buy rating on Palvella Therapeutics, retaining the price target of $90.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Sam Slutsky has given his Buy rating due to a combination of factors that highlight the potential of Palvella Therapeutics in addressing a significant unmet medical need. The recent publication by Gallagher et al. provides crucial epidemiological data on cutaneous venous malformations (CVMs), revealing a larger patient population than previously estimated. This underscores the opportunity for Palvella’s QTORIN 3.9% rapamycin, a topical formulation designed to effectively target these malformations.
Furthermore, the challenges associated with current CVM management, such as difficulty in early detection and limited effectiveness of existing therapies, emphasize the need for innovative solutions like Palvella’s product. With the Phase 2 TOIVA trial fully enrolled and results anticipated soon, there is a promising outlook for the company’s targeted treatment approach. These factors collectively support Slutsky’s positive outlook and Buy rating for Palvella Therapeutics.
In another report released yesterday, Cantor Fitzgerald also maintained a Buy rating on the stock with a $120.00 price target.